摘要
目的探讨对慢性乙型肝炎采用复方甘草酸苷联合恩替卡韦治疗的临床效果。方法选择2018年6月—2021年6月扬州市第三人民医院收治的100例慢性乙肝患者,以随机数表法分为对照组(n=50,恩替卡韦治疗)与观察组(n=50,恩替卡韦联合复方甘草酸苷治疗)。对比两组治疗后乙肝病毒血清标志物转阴率,检测治疗前后总胆红素(TBiL)、谷草转氨酶(AST)、谷丙转氨酶(ALT)评估患者肝功能,并统计两组不良反应发生情况。结果观察组HBeAb、HBeAg、HBsAg、HBV-DNA转阴率分别为44.00%、18.00%、52.00%、68.00%,均高于对照组,差异有统计学意义(χ^(2)=4.456、5.005、5.002、6.828,P<0.05)。观察组治疗后TBiL、AST、ALT水平分别为(16.21±4.41)μmol/L、(43.45±5.14)U/L、(35.71±12.23)U/L,均低于对照组,差异有统计学意义(t=5.358、24.848、8.927,P<0.05)。两组不良反应发生率(10.00%vs 8.00%)比较,差异无统计学意义(χ^(2)=0.000,P>0.05)。结论复方甘草酸苷联合恩替卡韦治疗慢性乙肝疗效可靠且可改善肝功能,安全性高。
Objective To explore the clinical effect of treatment of chronic hepatitis B with compound glycopyrrolate combined with entecavir.Methods 100 patients with chronic hepatitis B admitted to Yangzhou Third People’s Hospital from June 2018 to June 2021 were randomly divided into the control group(n=50,treated with entecavir)and the observation group(n=50,treated entecavir combined with compound glycyrrhizin).The negative rate of serum markers of hepatitis B virus after treatment was compared between the two groups,total bilirubin(TBiL),aspartate transaminase(AST)and alanine transaminase(ALT)were detected before and after treatment to evaluate the liver function of patients,and the adverse reactions of the two groups were counted.Results The rates of HBeAb,HBeAg,HBsAg and HBV-DNA conversion in the observation group were 44.00%,18.00%,52.00%and 68.00%,respectively,which were higher than those in the control group,and the differences were statistically significant(χ^(2)=4.456,5.005,5.002,6.828,P<0.05).The post-treatment TBiL,AST and ALT levels in the observation group were(16.21±4.41)μmol/L,(43.45±5.14)U/L and(35.71±12.23)U/L,respectively,which were lower than those in the control group,and the differences were statistically significant(t=5.358,24.848,8.927,P<0.05).The incidence of adverse reactions(10.00%vs 8.00%)was compared between the two groups,and the difference was not statistically significant(χ^(2)=0.000,P>0.05).Conclusion Compound glycyrrhizin combined with entecavir is reliable and can improve liver function with high safety in the treatment of chronic hepatitis B.
作者
李文颖
王靖
陆兴
LI Wenying;WANG Jing;LU Xing(Department of Hepatology,Yangzhou Third People's Hospital,Yangzhou,Jiangsu Province,225001 China;Department of Infection,Yangzhou Third People's Hospital,Yangzhou,Jiangsu Province,225001 China)
出处
《系统医学》
2022年第20期119-122,共4页
Systems Medicine
基金
中国公共卫生联盟课题(第一批)项目(GWLM202022)。
